Pipeline

We innovate to advance treatment standards for people with skin conditions worldwide.

Our robust portfolio of small molecules and antibodies allows us to meet the diverse medical needs of the patients we serve. Our scientists’ goal is to find functional cures enabling people with skin conditions to live free of symptoms.

LEO Pharma’s global R&D organisation is powered by more than 700 scientists and specialists who all possess in-depth knowledge of the skin. Together with our partners, we have built a strong pipeline in dermatology that covers several indications and addresses a wide range of medical needs. We are steadily expanding our pipeline with innovative topical, biologic and systemic treatments to bring life-changing medicines to people with skin diseases.

Today, people with skin diseases are treated with a wide variety of medicines such as topical creams and ointments, oral tablets and injectable biologics, depending on the severity of their disease. We acknowledge these different needs, and our aim is to discover and develop the safest and most effective treatments for all patient segments.

In addition, we explore opportunities to make treatment easier for patients through innovations within medical device technologies and digital solutions and services.

Our current pipeline includes:

  • Oral PDE4i: A systemic anti-inflammatory compound intended to offer a long-term oral treatment option for people with psoriasis.
  • Tralokinumab, an IL-13 antibody for systemic treatment of atopic dermatitis (phase II)
  • Delgocitinib: A topical treatment for inflammatory skin diseases using a pan-JAK inhibitor, intended to offer an improved safety profile compared to topical steroids.
  • SEGRA: A selective glucocorticoid non-steroidal receptor agonist for topical treatment of atopic dermatitis, intended to offer an improved safety profile compared to topical steroids.
  • ARGX-112: An anti-inflammatory monoclonal antibody for the treatment of atopic dermatitis.
  • JAK1 oral: A systemic anti-inflammatory JAK inhibitor intended to offer an oral treatment for people with moderate-to-severe atopic dermatitis.
  • JW1601: A novel atopic dermatitis drug candidate intended for oral treatment of atopic dermatitis which is expected to maximize efficacy by dual action of anti-pruritus (anti-itch) and anti-inflammation and minimize adverse events by high selectivity on the target.

In addition, we explore opportunities to make treatment easier for patients through innovations within medical device technologies and digital solutions and services.

Pipeline overview

Click image below to expand to full size view (pdf).

 

We use cookies on this website

The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information.

By continuing to browse our website, you are agreeing to our use of cookies

If you want to know more about our cookie policy and how to avoid and delete cookies click here.